I believe this to be correct, ohm. However, IMO, unless something drastically changes the pace of enrollment (yeah- we've been hearing about the new sites for months now), we're into February/March seeing data on 293. Why in the world did we basically drop the ball as soon as we hit 195? By February/March, we are likely to be behind BP sponsored APPROVED therapies in the battle against COVID, and despite showing efficacy, I don't think it was a silver bullet that would have stopped the trial now. With the SOC improving and new therapy on the way, we're going to have a tough time getting attention in this COVID space.